CD8A and neoplasm: CXCL8 modulates the TNBC immune microenvironment by controlling the infiltration of CD4+ and CD8+ T cells and increasing CD274 (PD-L1) expression, unveiling potential therapeutic targets for anti-tumor immunotherapy [42].